Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)

PURPOSE: The efficacy of levoketoconazole for endogenous Cushing’s syndrome was demonstrated in a phase 3, open-label study (SONICS). This study (LOGICS) evaluated drug-specificity of cortisol normalization. METHODS: LOGICS was a phase 3, placebo-controlled, randomized-withdrawal study with open-lab...

Descripción completa

Detalles Bibliográficos
Autores principales: Pivonello, Rosario, Zacharieva, Sabina, Elenkova, Atanaska, Tóth, Miklós, Shimon, Ilan, Stigliano, Antonio, Badiu, Corin, Brue, Thierry, Georgescu, Carmen Emanuela, Tsagarakis, Stylianos, Cohen, Fredric, Fleseriu, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675660/
https://www.ncbi.nlm.nih.gov/pubmed/36085339
http://dx.doi.org/10.1007/s11102-022-01263-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675660/
https://www.ncbi.nlm.nih.gov/pubmed/36085339
http://dx.doi.org/10.1007/s11102-022-01263-7

Ejemplares similares